TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05663255
Drug: Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
Study: NCT05181995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 50 mg NYX-783
Study: NCT05450549
Drug: DNL919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses
Study: NCT05450549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses
Study: NCT06473909
Drug: CD25 antibody combined glucocorticoid as first-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD25 antibody combined glucocorticoid as first-line treatment
Study: NCT04813445
Drug: Xingnaojing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study: NCT05198505
Drug: TQB2868 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
Study: NCT06597682
Drug: Vitamin C combined with Coenzyme Q10 oral treatment
Normalized name: vitamin C combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 4 weeks of treatment
Study: NCT06601127
Drug: Tiprogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
Study: NCT06444594
Drug: TRPV1 Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: camphor gel 5-20%
Study: NCT06444594
Drug: TRPM8, TRPV4, TRPV1 Agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
Study: NCT06597422
Drug: STSP-0902 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, single dose
Study: NCT06597422
Drug: STSP-0902 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, single dose
Study: NCT05358808
Drug: TCB008
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
Study: NCT05808972
Drug: Ringer lactate (RL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
Study: NCT06597422
Drug: STSP-0902 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, three times daily for a total of 8 days
Study: NCT06597422
Drug: STSP-0902 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, six times daily for a total of 8 days
Study: NCT06597422
Drug: STSP-0902 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, multiple doses
Study: NCT06597422
Drug: STSP-0902 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, single dose, tear samples will be collected
Study: NCT05841693
Drug: Carbohydrate
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
Study: NCT06315387
Drug: 4-MUST, 1 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-methylumbelliferyl trimebutine sulfate, 128 mg
Study: NCT06315387
Drug: 4-MUST, 2 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-methylumbelliferyl trimebutine sulfate, 256 mg
Study: NCT06315387
Drug: 4-MUST, 3 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-methylumbelliferyl trimebutine sulfate, 384 mg
Study: NCT04659096
Drug: ION537
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION537 will be administered by IV injection.
Study: NCT05422703
Drug: Proteolytic enzymes
Normalized name: Proteolytic enzymes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
Study: NCT04766398
Drug: KHK7791
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04766398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05830747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative Placebo administration before third molar surgery
Study: NCT05462717
Drug: RMC-6291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet once or twice a day
Study: NCT01412359
Drug: Omegaven®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
Study: NCT04857333
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: For pulmonary nodules with features of infectious disease, antibiotics is recommended
Study: NCT02963350
Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05947097
Drug: HSK21542 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ug/kg bolus for 2min±5s
Study: NCT05178524
Drug: BIFICO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
Study: NCT04945096
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
Study: NCT06602739
Drug: REGN5715
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per protocol
Study: NCT06602739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per protocol
Study: NCT06597396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT06587217
Drug: Carbidopa-Levodopa 25/100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Study: NCT06108362
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
Study: NCT06503224
Drug: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
Study: NCT06463327
Drug: TCB008
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
Study: NCT06603571
Drug: LY3841136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06603077
Drug: AVTX-009 Regimen 1
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVTX-009 will be administered as a subcutaneous injection every 4 weeks.
Study: NCT06603077
Drug: AVTX-009 Regimen 2
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVTX-009 will be administered as a subcutaneous injection every 2 weeks.
Study: NCT06603077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as a subcutaneous injection every 2 weeks.
Study: NCT06599528
Drug: T-R (Test-Reference drug)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
Study: NCT06599528
Drug: R-T (Reference-Test drug)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
Study: NCT06602466
Drug: Test toothpaste
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
Study: NCT05883956
Drug: Oral decitabine/cedazuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
Study: NCT06403150
Drug: Fosphenytoin Injection
Normalized name: fosphenytoin Injection
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
Study: NCT06036589
Drug: CA and BAM8-22
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT06036589
Drug: Vehicle and BAM8-22 application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT06036589
Drug: vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
Study: NCT06593600
Drug: REGN7544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration
Study: NCT06593600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration
Study: NCT04991584
Drug: Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
Study: NCT05150405
Drug: QLF31907
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
Study: NCT05263505
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target dose: 20mg weekly
Study: NCT05263505
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target dose: 2mg/kg daily
Study: NCT05692154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine matching placebo oral tablet
Study: NCT06293807
Drug: Xylocaine 2 % with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic used during dental procedures
Study: NCT06293807
Drug: Bupivicaine 0.5% with 1:200,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic used during dental procedures
Study: NCT05654753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
Study: NCT06037434
Drug: Spironolactone Tablets
Normalized name: Spironolactone Tablets
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-4mg/kg, bid
Study: NCT05065619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Study: NCT05160220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g dried edible non-psychoactive mushroom material.
Study: NCT04976023
Drug: Yupingfeng Powder granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.5 5 g twice daily for 8 weeks
Study: NCT05629325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of treatment with placebo
Study: NCT05141305
Drug: standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
Study: NCT04959032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally, once daily.
Study: NCT05684380
Drug: MAZ-101association
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT05684380
Drug: DYMISTA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator
Study: NCT06768580
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive one capsule of melatonin (5mg) orally the night before surgery at 9 pm, the night of the operation, and two nights after the surgical operation at 9 pm, also the patients will receive 10 ml bolus of saline intravenous (IV) over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) until the end of surgery.
Study: NCT06768580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a bolus (10 ml) of saline over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) and placebo capsule the night before surgery at 9 pm, the night of the operation and two nights after the surgical operation at 9 pm.
Study: NCT06768944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive placebo
Study: NCT05036005
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
Study: NCT06248645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
Study: NCT06152978
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Study: NCT00031057
Drug: Thiamine hydrochloride
Normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05841394
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
Study: NCT05841394
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
Study: NCT06768840
Drug: oral mini pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
Study: NCT04789330
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine administered during anesthesia
Study: NCT05481931
Drug: prabotulinumtoxinA
Normalized name: PrabotulinumtoxinA
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Botulinum toxin Type A powder for solution for injection
Study: NCT05076682
Drug: Choline
Normalized name: Choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline 300mg tid or 500mg bid, p.o
Study: NCT05852873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
Study: NCT03942211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
Study: NCT01211951
Drug: KCT-0809
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04724148
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To assess the accuracy of HVPG in TIPS after injecting a dose of 1\~2 mg/kg fentanyl.
Study: NCT01211951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05514340
Drug: Sovateltide along with standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
Study: NCT04380233
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Study: NCT04726215
Drug: [18F]F AraG
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging agent specific to activated T cells
Study: NCT05814068
Drug: antihypertensive drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with hypertension will be treated for it by their physician
Study: NCT04541550
Drug: AMP-001 Medium Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
Study: NCT06298071
Drug: SIBP-R002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Study: NCT06298071
Drug: SIBP-R002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Study: NCT06298071
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination drugs: Methotrexate, dose15 mg, oral.
Study: NCT06299709
Drug: VNZ/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC granules for oral administration.
Study: NCT06201507
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.
Study: NCT05050604
Drug: Placebo of Choline Alfoscerate 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
Study: NCT06474052
Drug: Gelofusine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
Study: NCT06208033
Drug: SMET12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study: NCT06208033
Drug: SMET12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study: NCT06208033
Drug: SMET12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study: NCT05184218
Drug: IGM-6268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05184218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05784350
Drug: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.
Study: NCT06431490
Drug: TQB2102 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)